Orexin and sleep quality in anorexia nervosa: Clinical relevance and influence on treatment outcome
Scholar | Otros documentos del autor: Sauchelli, Sarah; Jiménez Murcia, Susana; Sánchez, Isabel; Riesco, Nadine; Custal, Nuria; Garrido; Fernández García, José Carlos; Garrido-Sánchez, Lourdes; Tinahones Madueño, Francisco Javier; Steiger, Howard; Israel, Mimi; Baños Rivera, Rosa María; Botella, Cristina; De la Torre, Rafael; Fernández-Real, José Manuel; Ortega, Francisco J.; Frühbeck, Gema; Granero, Roser; Tárrega, Salomé; Crujeiras, Ana B.; Rodríguez, Amaia; Estivill, Xavier; Beckmann, Jacques S.; Casanueva, Felipe F.
MetadatosMostrar el registro completo del ítem
TítuloOrexin and sleep quality in anorexia nervosa: Clinical relevance and influence on treatment outcome
Fecha de publicación2016
Versión del editorhttp://www.sciencedirect.com/science/article/pii/S030645301530038X
Background and aims Orexins/hypocretins are orexigenic peptides implicated in the regulation of feeding behavior and the sleep/wake cycle. Little is known about the functioning of these peptides in anorexia nervosa ... [+]
Background and aims Orexins/hypocretins are orexigenic peptides implicated in the regulation of feeding behavior and the sleep/wake cycle. Little is known about the functioning of these peptides in anorexia nervosa (AN). The aims of the current study were to evaluate the extent to which orexin-A might be linked to sleep and treatment outcome in AN. Method Fasting plasma orexin-A concentrations were measured in 48 females with AN at the start of a day hospital treatment and in 98 normal-eater/healthy-weight controls. The Pittsburgh Sleep Quality Index was administered at the beginning of the treatment as a measure of sleep quality. Other psychopathological variables were evaluated with the Symptom Checklist-Revised (SCL90R) and the Eating Disorder Inventory-2 (EDI). Patients were assessed at the start and end of treatment by means of commonly used diagnostic criteria and clinical questionnaires. Results The AN patients presented more sleep disturbances and poorer overall sleep quality than did the healthy controls (p = .026) but there were no global differences between groups in plasma orexin-A concentrations (p = .071). In the AN sample, orexin-A concentrations were associated with greater sleep disturbances (|r| = .30), sleep inefficiency (|r| = .22) and poorer overall sleep (|r| = .22). Structural Equation Modeling (SEM) showed that both elevated orexin-A concentrations and inadequate sleep predicted poorer treatment outcome. Conclusion Plasma orexin-A concentrations contribute to poor sleep quality in AN, and both of these variables are associated with therapy response. [-]
Palabras clave / Materias
Tipo de documentoinfo:eu-repo/semantics/article
Derechos de acceso
© 2015 Elsevier Ltd. All rights reserved.
Aparece en las colecciones
- PSB_Articles